FLT3 and acute myeloid leukemia: Another first generation FLT3 inhibitor, Lestaurtinib (previously known as CEP-701), is a relatively less selective compound compared to midostaurin, and its usage has not been able to improve the survival in FLT3 mutated AML patients (Knapper et al., 2017).